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Summary 
Gated radionuclide ventriculograms were performed to evaluate cardiac function in 53 patients who received 
doxorubicin treatment for various malignancies (mean dose: 449 + 128 mg/m2BSA). In fourteen patients 
(Group I) function was evaluated before and after treatment; there was a significant decrease of resting left 
ventricular ejection fraction after therapy (p<0.001). Twenty-two patients (Group II) had serial studies 
during treatment which also showed a significant fall of resting left ventricular ejection fraction (p<0.001). 
Eighteen patients in Groups I and II had supine exercise studies. A normal exercise response was maintained 
in the majority of patients. Exercise testing added little to the diagnostic performance when compared to 
serial resting studies. We found regional wall motion abnormalities (mild apical hypokinesis) at rest by visual 
inspection in 33 of 36 Group I and Group II patients who had received doxorubicin. In the baseline or initial 
study, only 4 of these patients demonstrated WMA. In 18 Group I and II patients who were exercised, 3 had 
wall motion abnormalities during the initial study. All of these patients demonstrated wall motion ab- 
normalities at rest after the second study, however only 7 of 18 demonstrated abnormalities during the 
exercise study. 
The results indicate that resting left ventricular ejection fraction declines after doxorubicin treatment. 
Exercise radionuclide angiography may not increase diagnostic accuracy for the detection of doxorubicin 
related cardiotoxicity. Regional wall motion abnormalities occur with a relatively high incidence following 
doxorubicin therapy, more readily detectable at rest. However, the exercise study can distinguish doxorub- 
icin related wall motion abnormalities from those due to coronary artery disease. 
Introduction 
Doxorubicin is an effective chemotherapeutic 
agent for the treatment of malignant neoplastic 
disease [1-7]. Unfortunately, the amount of doxo- 
rubicin that can be administered is limited by its 
well known cardiotoxicity [8-13]. Toxic effects oc- 
cur acutely, mainly in form of transient benign 
arrhythmias [14, 15] and chronically, by develop- 
ment of dilated cardiomyopathy [8-13, 16, 17]. The 
degree of cardiotoxicity is generally thought to be a 
function of the cumulative dose [2-14]. However, 
the susceptibility to the toxic effects of doxorubicin 
varies considerably between patients [3, 6, 9, 18- 
24]. 
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Cardiotoxicity has been observed with several 
methods such as ECG [9, 25-27], systolic time in- 
tervals [28-30], echocardiography [31-33], radio- 
nuclide ventriculography [14, 18, 19, 22, 3436],  
cardiac catheterization and endomyocardial biopsy 
[4, 23, 29, 37]. However, morphologic monitoring 
by endomyocardial biopsy is of limited value in 
predicting development of cardiotoxicity [4, 38]. In 
contrast, monitoring cardiac function may be more 
sensitive for detecting early cardiotoxicity [19, 23, 
36]. Radionuclide ventriculography is an accurate 
and reproducible means for evaluating cardiac 
function and its functional reserve. Previous stud- 
ies revealed a decline in resting left ventricular 
ejection fraction [2-4, 6-11, 14-23]. Several studies 
also suggested that an exercise test increases the 
sensitivity of early detection of doxorubicin cardio- 
toxicity [16, 19, 23, 38]. 
The purpose of this study was to evaluate the 
effects of doxorubicin on left ventricular function 
at rest and exercise in order to define the diagnostic 
benefit of exercise testing in comparison to serial 
evaluation of resting function. Additionally, we 
investigated the incidence of regional wall motion 
abnormalities in doxorubicin treated patients, its 
relationship to the dose administered, and its re- 
sponse to exercise. 
Methods 
Study population 
The study population consisted of 53 patients (25 
males, 28 females) 18 to 76 years of age with an 
average of 51 years. A mean dose of doxorubicin 
449.3 + 128 mg/m 2 BSA was administered in these 
patients for treatment of neoplastic diseases at the 
time of the study. Care was taken to exclude pa- 
tients with evidence of coronary artery disease and/ 
or valvular heart disease by history, physical exam- 
ination and ECG criteria. 
Of the 53 patients, 36 had multiple radionuclide 
studies and were divided into two groups. In 14 
Group I patients, a baseline study was done prior to 
doxorubicin treatment and repeated two months 
after the last dose of doxorubicin. The mean in- 
terval between the two studies was 6 + 3.2 months. 
Among them, 7 patients had an exercise test. In 
Group II, serial studies were performed during 
doxorubicin treatment in 22 patients and among 
them, t l  patients had an exercise test; the mean 
interval between both studies was 7 + 3.3 months. 
Radionuclide technique 
Data acqu&ition 
For multiple ECG gated equilibrium blood pool 
imaging of the heart, 20 mCi of technetium-99m 
pertechnetate in vitro labeled autologous red blood 
cells were injected intravenously. Imaging was per- 
formed with a standard gamma camera (Series 420 
Mobile Gamma Camera, Technicare) equipped 
with a high-resolution, low-energy, parallel hole 
collimator [39]. In brief, the detector was tilted 10 
to 15 degrees caudally and the left anterior oblique 
(LAO) projection was adjusted until the left and 
right ventricle were optimally separated on the per- 
sistence scope. The image data were acquired with 
a dedicated nuclear medicine minicomputer (VIP 
550, Technicare) and formatted into a 64 by 64 
matrix. Data were recorded for 4 minutes at rest 
and for 3 minutes during exercise. 
Supine exercise was performed using a bicycle 
ergometer (Collins Pedal Mode) as described pre- 
viously [39, 40]. After the resting study, bicycle 
exercise was begun at a workload of 25 watts, and 
was increased every 4 minutes at each workload. 
Exercise was continued until shortness of breath, 
and/or fatigue occurred. Blood pressure and heart 
rate were recorded during the final minutes at each 
workload. 
Data processing 
The left. ventricular ejection fraction was calculated 
from the left ventricular time activity curve, con- 
structed from the 16 sequential equilibrium cardiac 
blood pool images. A 'variable' region of interest 
was assigned manually to the LV on each of the 16 
frames, and ejection fraction was calculated from 
the time activity (volume) curve as the difference 
between maximum and minimum counts, divided 
by the maximum counts [41]. 
Regional wall motion abnormalities were as- 
sessed visually by two experienced observers. The 
findings were defined as hypokinesis, akinesis, and 
dyskinesis, as described earlier [39, 40]. 
Additionally, synchronicity of regional wall mo- 
tion was assessed by phase analysis. The phase 
analysis of images was performed as described pre- 
viously [39, 41]. Using the discrete Fourier trans- 
form, the amplitude image is used to create a mask 
over the phase image. Only those pixels with an 
amplitude above a certain manually selected 
threshold (usually 10% of the maximum ampli- 
tude) are displayed and counted, so that the pixels 
outside the heart do not contribute to the phase 
distribution histogram. From the masked phase 
image, a histogram of the phase distribution from 0 
to 360 degrees on the abscissa, and the number of 
pixels within each 9 degree range on the ordinate, is 
generated. The left ventricle is manually outlined 
on the end-diastolic frame and a second histogram 
of the phase distribution is plotted and automat- 
ically analyzed. The mean phase of the ventricular 
peak is measured, as well as the standard deviation 
from the mean of the peak. The standard deviation 
of the peak describes the width of the peak and is 
used as an index of synchronicity of LV wall mo- 
tion. A standard deviation of 12 ° was defined as the 
upper limit of normal in a study in normal volun- 
teers. On the phase image, the localization of any 
segment with out-of-phase wall motion as well as 
any changes in phase distribution from rest to exer- 
cise are noted and compared to the visually as- 
sessed wall motion abnormalities. 
Statistical analysis 
Student's t-test for paired and unpaired data is 
employed to evaluate inter-group differences for 
statistical significance. All mean values are given 
with one standard deviation (SD) and comparisons 




Left ventricular function at rest and during exercise 
The relationship of left ventricular function, ex- 
pressed as global left ventricular ejection fraction, 
and the amount of doxorubicin received in the 
cohort of 53 patients is displayed in Fig. 1. There 
was no linear correlation found (r = 0.026N.S.). 
The mean left ventricular ejection fraction was 
47.0 + 6.6%, the mean dose of doxorubicin 449 + 
128 mg/m 2 BSA. For 29 patients receiving less than 
450 mg/m 2 doxorubicin, the ejection fraction aver- 
aged 48.6 + 6.0%, while in the 24 patients with 
more than 450mg/m 2, the mean ejection fraction 
was 45.3_+ 6.1% (p<0.05). 
Fig. 2 summarizes the results obtained at rest and 
during exercise in 30 patients. In 15 patients receiv- 
ing less than 450 mg/m 2 doxorubicin, the ejection 
fraction increased to 52.1 +_ 5.9%. In 15 patients 
with a dose of more than 450mg%, the exercise 
ejection fraction during exercise was not signif- 
icantly different from baseline value. Nine of the 15 
patients receiving less than 450 mg/m 2 had a normal 
exercise left ventricular ejection fraction response 
of more than 5% increase, while only 7 of 16 with 
more than 450 mg/m 2 demonstrated an increase of 
more than 5% (n.s). 
Group I: Patients studied before and after treatment 
In the 14 Group I patients who were studied before 
and after doxorubicin treatment (Fig. 3), the rest- 
ing LVEF before treatment was 54.6 + 4.9% and 
decreased significantly to 45.4 + 6.2% after treat- 
ment (p<0.001). In 7 patients in this group, the 
rest and exercise left ventricular ejection fraction 
before and after treatment of doxorubicin was de- 
termined. The resting left ventricular ejection frac- 
tion before doxorubicin treatment was 52.9 + 
5.0% and increased significantly to 62.7 + 6.8% 
with exercise (p<0.001); the resting left ventric- 
ular ejection fraction after doxorubicin treatment 
was 45.9 + 6.6% and increased significantly to 
51.4 + 7.7% with exercise (p<0.01). Six of 7 pa- 
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Fig. 1. Relationship between resting left ventricular ejection 
fraction (LVEF) and cumulative doxorubicin dose in 53 pa- 
tients. 
tion more than, or equal to, 5% during the baseline 
exercise test, while 5 of 7 increased more than, or 
equal to 5% during the second test. The heart rate 
response (120.4 + 16.9bpm vs 119.1_+ 17.8bpm) 
and maximum work load (74.4 + 17.2 watts vs 
68.2 + 23.2 watts) were not significantly different 
for both exercise tests. 
Group H: Patients studied serially during treatment 
In the 22 Group II patients, serial studies during 
treatment with doxorubicin were performed (Fig. 
4). The resting left ventricular ejection fraction of 
initial studies was 53.1 + 6.2%, and decreased to 
46.9 + 7.7% in follow-up studies (p;<0.001). 
In 11 patients of this group, serial studies with 
exercise were performed. The resting left ventric- 
ular ejection fraction of the initial studies was 
50.1 + 6.0% and increased significantly to 57.3 + 
9.6% during exercise (p<0.001); the resting left 
ventricular ejection fraction of follow-up studies 
was 46.3 + 6.8% and increased significantly to 
50.1 + 6.9% during exercise (p<0.05) which was 
significantly less than in the initial exercise study 
(p<0.01). Eight of 11 patients had a normal ven- 
tricular exercise response during the first study, 6 
of 11 during the second study. There were no signif- 
icant differences between both exercise tests in 
heart rate response (116.9 + 17.7bpm vs 113.6 + 
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Fig. 2. Response of left ventricular ejection fraction (LVEF) to 
exercise in 30 patients. The patients were divided into two 
groups based on accumulated doxorubicin dose. 
20.12bpm) and work load (63.6 + 23.4 watts vs 
56.7 + 25.4 watts). 
Regional wall motion abnormalities 
In the majority of our patients on doxorubicin 
treatment, regional wall motion abnormalities 
were observed, which were characterized in all 
cases by apical hypokinesis. The wall motion ab- 
normality occurred post-treatment in 68% of the 
entire 53 patients studied at rest. The incidence of 
wall motion abnormalities was 55% (16 Of 27 pa- 
tients who received less than 450 mg/m 2 of doxo- 
rubicin), but 83% (20 of 22) in patients who re- 
ceived more than, or equal to, 450 mg/m 2 of doxo- 
rubicin. The wall motion abnormalities in the 30 
patients with an exercise test occurred in 73% (22) 
at rest, and in 47% (14) during exercise. In the 15 
patients.who received less than 450 mg/m 2 of doxo- 
rubicin, the wall motion abnormality occurred in 
57% (8) at rest and in 21% (3) during exercise. In 
the 15 patients who received more than 450 mg/m 2 
of doxorubicin, the wall motion abnormality oc- 
curred in 87% (14) at rest and in 69% (11) during 
exercise. 
No wall motion abnormality at rest was observed 
in the 14 Group I patients before doxorubicin treat- 
ment, but a wall motion abnormality at rest oc- 
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Fig. 3. Rest and exercise left ventricular ejection fraction in 14 
Group I patients before and after doxorubicin treatment. Serial 
resting studies were performed in 14 patients (dotted line). 
Seven of these 14 patients underwent exercise before and after 
treatment (solid line). 
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Fig. 4. Rest and exercise left ventricular ejection fraction in 22 
Group II patients during doxorubicin treatment. Serialleft ven- 
tricular ejection fractions at rest were determined in 22 patients 
during treatment (dotted line). Exercise studies (solid line) 
were performed in 11 of the 22 patients. 
The wall motion abnormality at rest in 22 Group II 
patients occurred in 18% (4) in the initial studies 
and in 80% (20) in the follow-up studies. 
Phase analysis 
Phase analysis of images were performed for 
Group I and II patients to confirm the wall motion 
abnormality described visually. Phase analysis can 
be used to assess synchronicity of ventricular wall 
motion which is quantitated using the standard de- 
viation of the left ventricular peak in the phase 
distribution histogram. In normals, the standard 
deviation of the left ventricular peak has been 
found to be below 12 ° at rest and 10 ° during exer- 
cise. 
In 14 Group I patients, the standard deviation of 
the left ventricle before treatment was 9.6 _+ 1.7 ° at 
rest and increased significantly to 12.8 + 3.0 ° after 
doxorubicin treatment (p<0.001). For 7 patients 
with an exercise test before and after treatment, 
the standard deviation at exercise was unchanged 
with 9.9 + 1.7 ° before and 9.6 + 1.9 after treat- 
ment (NS). 
In 22 Group II patients, the standard deviation 
of the left ventricle on initial studies was 10.4 _+ 
1.9 ° at rest and increased significantly to 12.5 _+ 
3.1 ° on follow-up studies during doxorubicin treat- 
ment (p<0.01). In 11 patients with serial exercise 
testing, the standard deviation was 10.1 _ 1.4 ° and 
9.8 + 1.9 ° respectively during the two studies with 
exercise without significant difference (NS). 
Discussion 
The results of this study confirm earlier reports on 
the cardiotoxic effect of doxorubicin and its rela- 
tionship to the cumulative dose of the drug [2-14]. 
The mean ejection fraction in the group receiving 
more than 450 mg/m 2 was significantly lower than 
in the group receiving less than 450 mg/m 2. How- 
ever, the variation in ejection fractions for a given 
dose was considerable, these precluding a signif- 
icant linear correlation between dose and ejection 
fraction. The left ventricular ejection fraction used 
in this study as well as in previous investigations as 
a parameter of left ventricular function does not 
directly reflect cardiac contractility, but rather the 
combined effect of preload, afterload and contrac- 
tility. Since no other hemodynamic measurements 
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besides ejection fraction were made in this study, 
part of the observed interindividual variation of the 
drug effect may be explained by the choice of this 
parameter for left ventricular function. 
In our patient population, 33 of 53 patients had 
an abnormal ejection fraction (<50%) after treat- 
ment. The incidence of an abnormal ejection frac- 
tion was slightly higher (19/26) in the patients re- 
ceiving more than, or equal to, 450 mg/m 2, as com- 
pared to patients receiving less than 450 mg/m 2 (14/ 
27). The data however show that in 20 of the 53 
patients, the ejection fraction.remained within nor- 
mal limits and that some patients even maintained 
a normal ejection fraction after exposure to large 
doses of doxorubicin, indicating a considerable in- 
terindividual variation in the susceptibility to the 
cardiotoxic effect of doxorubicin. 
In earlier reports it has been stated that exercise 
studies increase the sensitivity of early detection of 
doxorubicin induced cardiomyopathy [16, 19, 23, 
38]. In the 30 patients undergoing treatment with 
doxorubicin, 14 had an abnormal exercise re- 
sponse, defined as a failure to increase LVEF by 
more than 5%. However, only three of these had a 
normal resting LVEF. Thus, in this group of pa- 
tients, exercise added little diagnostic information 
for detection of abnormal ventricular function. 
The failure to increase ejection fraction during 
exercise is commonly thought to be a sensitive sign 
of ventricular dysfunction, most widely used as 
diagnostic criteria in patients suspected of coronary 
artery disease [43--45]. An abnormal exercise re- 
sponse, however, is not specific for any cardiac 
disease and has even been found in a considerable 
number of normal female subjects [46]. Since pa- 
tients on doxorubicin treatment generally repre- 
sent a mixed population with unknown prevalence 
of asymptomatic coronary artery disease, an ab- 
normal exercise response, especially in the older 
age group, may not be specific for doxorubicin 
induced cardiomyopathy. We attempted in our 
study population to carefully exclude the patients 
with clinical evidence of coronary artery disease, 
but only a few patients had proven normal coro- 
nary arteries by angiography. None of the patients 
developed chest pain or ischemic ECG changes 
during exercise. Additionally, patients treated for 
neoplastic diseases often have limited exercise tol- 
erance because of their primary disease, which fur- 
ther limits the diagnostic value of the exercise 
test.The data on heart rate response and the mean 
work load in our patients indicate that the exercise 
level was submaximal in most cases. 
With serial studies at rest, the effect of doxorub- 
icin on LV function can be assessed more specifi- 
cally since rapid development of coronary artery 
disease within a few months rarely occurs and 
changes of cardiac performance most likely reflect 
the effect of the therapeutic intevention. In the 
Group I patients studies before and after doxorub- 
icin, 5 of 7 patients maintained a normal exercise 
response, with a new abnormal exercise response 
present in 2 of 7 patients. However, the resting 
ejection fraction decreased in 12 of 14 patients 
when the baseline value was compared with the 
post-treatment value. These data suggest that the 
change in resting function is more sensitive than the 
exercise response in detecting the toxic effects of 
doxorubicin. The same trend could be demonstrat- 
ed in Group II patients with serial studies during 
treatment. Seven of 11 patients maintained a nor- 
mal exercise response with 4 new abnormal re- 
sponses, while 17/22 demonstrate a further de- 
crease in resting function. Therefore, we conclude 
that serial determination of resting ejection frac- 
tion in patients receiving doxorubicin is most sensi- 
tive and specific for the evaluation of the cardiotox- 
ic effect. 
Regional left ventricular wall motion abnormal- 
ities are common in patients with coronary artery 
disease, but have also been described in patients 
with other cardiac diseases such as valvular heart 
disease and cardiomyopathies [39, 47-50]. Region- 
al impairment of wall motion has, to our knowl- 
edge, not been reported in patients receiving doxo- 
rubicin treatment. In view of the relatively high 
incidence (68% at rest in 53 patients), silent coro- 
nary artery disease as the etiologic factor appears 
to be unlikely. In addition, the incidence of region- 
al wall motion abnormalities decreased during ex- 
ercise, a finding not consistent with ischemic heart 
disease. Wall motion abnormalities occurred more 
often in patients who received more than 
450mg/m 2 of doxorubicin, and hence, paralleled 
the impairment of global left ventricular function. 
This dose dependence is further substantiated by 
the fact that the incidence of wall motion abnor- 
malities increased in patients with serial studies 
during treatment. In all cases the wall motion ab- 
normality involved the apex of the left ventricle, a 
segment which is also affected in patients with val- 
vular heart disease [39, 49, 50]. 
The morphologic findings of doxorubicin cardio- 
myopathy are similar to those found in dilated car- 
diomyopathy and may represent diffuse myocar- 
dial involvement rather than a focal lesion [3, 7, 23, 
29, 37]. Therefore, we hypothesize that the region- 
al impairment described above reflects a functional 
abnormality caused by change of left ventricular 
geometry. Since doxorubicin has been shown to 
cause dilatation of the heart [3, 5], changes in load- 
ing conditions could lead to a regional decrease of 
myocardial fiber shortening. During exercise and a 
concomitant increase of adrenergic stimulation, 
these regional differences in loading conditions 
may be overriden, and may explain the improve- 
ment of regional wall motion during exercise. 
Phase analysis is a more objective way to eval- 
uate synchron~ of the left ventricular contraction 
pattern and has been used to quantitate the tempo- 
ral sequence of regional wall motion [39, 41, 42]. 
The measurements of the standard deviation of the 
left ventricular phase distribution in our study con- 
firms a visual impression. We did find an increase 
of standard deviation in serial studies reflecting less 
synchrony of contraction. This finding paralleled 
the increased incidence of visually observed wall 
motion abnormalities. The standard deviation de- 
creased during exercise, again consistent with the 
visually obtained improvement of wall motion ab- 
normalities. In contrast, it has been shown that in 
patients with coronary artery disease and exercise 
induced ischemia, standard deviation increased 
markedly during exercise [39]. The discrepancy be- 
tween our findings and an ischemic phase pattern 
further suggests that the observed wall motion ab- 
normalities are due to the effect of doxorubicin, 




We conclude from this study that the cardiotoxic 
effect of doxorubicin can be monitored best by 
serial resting ventricular function studies. Exercise 
testing may increase the sensitivity of detection of 
ventricular dysfunction if only one study during 
treatment is done, but the known low specificity of 
the ventricular exercise response offsets the diag- 
nostic gain. Regional wall motion abnormalities 
occur with a relatively high incidence in patients 
undergoing doxorubicin treatment and are more 
often detectable at resting conditions. In fact, they 
frequently disappear with exercise. The results of 
phase analysis which allows objective assessment 
of synchrony of left ventricular wall motion sup- 
ports the visual observation of regional wall motion 
abnormalities. 
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